Trial Profile
A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ferric citrate (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Sponsors Keryx Biopharmaceuticals
- 04 Apr 2018 Results published in the Keryx Biopharmaceuticals Media Release
- 04 Apr 2018 According to Keryx Biopharmaceuticals media release, post-hoc data from this study is published in the online issue of the American Journal of Hematology.
- 07 Nov 2017 According to Keryx Biopharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has approved Auryxia for the treatment of iron deficiency anemia in adults with chronic kidney disease (CKD), not on dialysis. The sNDA was based on data from this trial.